ImmuneOnco Biopharmaceuticals (Shanghai) Full Year 2024 Earnings: CN¥0.84 loss per share (vs CN¥1.05 loss in FY 2023)

ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) Full Year 2024 Results

Key Financial Results

• Revenue: CN¥79.5m (up by CN¥71.8m from FY 2023).
• Net loss: CN¥315.9m (loss narrowed by 17% from FY 2023).
• CN¥0.84 loss per share (improved from CN¥1.05 loss in FY 2023).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

1541 Products In Clinical Trials

• Phase I: 12.
• Phase III: 2.

All figures shown in the chart above are for the trailing 12 month (TTM) period

The primary driver behind last 12 months revenue was the United States of America segment contributing a total revenue of CN¥74.0m (93% of total revenue). The largest operating expense was Research & Development (R&D) costs, amounting to CN¥322.8m (82% of total expenses). Explore how 1541's revenue and expenses shape its earnings.

ImmuneOnco Biopharmaceuticals (Shanghai) shares are down 2.3% from a week ago.

Risk Analysis

It is worth noting though that we have found 1 warning sign for ImmuneOnco Biopharmaceuticals (Shanghai) that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.